Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?
Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026? The Motley Fool
Covered in this story
What has happened since
- Amgen is up 0.0% since this was published.
- Vertex Pharmaceuticals is up 0.0% since this was published.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Amgen
- Scotiabank: $403 → $500 by Oct 2027 via AD HOC NEWS
- Scotiabank: $424 → $500 by Sep 2027 · Sector Outperform via GuruFocus
- UBS: $408 → $440 by Aug 2027 · Buy via GuruFocus
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $AMGN yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Amgen →Dalsna Finance is currently tracking 50 stories mentioning Amgen, the earliest published 2 Jul 2026.
Summary aggregated from The Motley Fool's public RSS feed. The full reporting belongs to The Motley Fool — please read it on their site.